You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Dow
Express Scripts
Baxter
Moodys
Boehringer Ingelheim

Last Updated: September 30, 2020

DrugPatentWatch Database Preview

Litigation Details for Forest Laboratories Holdings Ltd. v. Apotex Corp. (D. Del. 2013)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Small Molecule Drugs cited in Forest Laboratories Holdings Ltd. v. Apotex Corp.
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for Forest Laboratories Holdings Ltd. v. Apotex Corp. (D. Del. 2013)

Date Filed Document No. Description Snippet Link To Document
2013-09-23 1 23. United States Patent No. 6,602,911 (“the ’911 patent”), titled “Methods of Treating… a) declare that United States Patent Nos. 6,602,911, 7,888,342, and 7,994,220 are valid; …(2)(A), Apotex infringed United States Patent Nos. 6,602,911, 7,888,342, and 7,994,220 by submitting …prior to the expiration of United States Patent Nos. 6,602,911, 7,888,342, and 7,994,220 would constitute…than the expiration date of United States Patent Nos. 6,602,911, 7,888,342, and 7,994,220, including any External link to document
2015-12-09 251 the "use code" submitted for U.S. Patent No. 7,994,220 ("the '220 patent") to the Food & Drug Administration…23 September 2013 1:13-cv-01602 830 Patent None District Court, D. Delaware External link to document
2016-01-20 259 of U.S. Patent No. 6,602,911 (“the ‘911 Patent”), U.S. Patent No. 7,888,342 (“the ‘342 Patent”), and …statutory presumption that the ‘911 Patent, the ‘342 Patent, and the ‘220 Patent are valid and enforceable in…counterclaims that the ‘911 Patent, the ‘342 Patent, and the ‘220 Patent are invalid, unenforceable and… the expiration of the ‘911 Patent, the ‘342 Patent, and the ‘220 Patent was a technical act of infringement… counterclaims that the ‘911 Patent, the ‘342 Patent, and the ‘220 Patent are invalid, unenforceable External link to document
2016-07-11 286 .S. Patent Nos. 6,602,911 ("the '911 patent"), 7,888,342 ("the '342 patent"…the '220 patent") (collectively, "the patents-in-suit"). The patents-in-suit are currently…'911 patent, claims 1-10 of the '342 patent, and claims 1-7 of the '220 patent. (Civ. No.…#39;911 patent, claims 1, 2 and 6 of the '342 patent, and claim 1 of the '220 patent pursuant…;911 patent at 16:14-15) b. The '342 patent The '342 patent, filed External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
Johnson and Johnson
Express Scripts
Boehringer Ingelheim
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.